Publications by authors named "J-J Grob"

Claim this Profile
A
A Phase I, First-in-Human, Dose-Escalation, Expansion Trial of Cytokine-Encoding Synthetic mRNA Mixture Alone or with Cemiplimab in Advanced Solid Tumors.
Oliver Bechter, Carmen Loquai, Stephane Champiat, Jean-Francois Baurain, Jean-Jacques Grob

Clin Cancer Res· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase Ib Study of Immunocytokine Simlukafusp Alfa (FAP-IL2v) Combined with Pembrolizumab for Treatment of Advanced and/or Metastatic Melanoma.
Eva Munoz-Couselo, Ainara Soria Rivas, Shahneen Sandhu, Georgina V Long, Miguel F Sanmamed, Jean-Jacques Grob

Cancer Res Commun· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term outcomes among patients who respond within the first year to nivolumab plus ipilimumab or nivolumab monotherapy: A pooled analysis in 935 patients.
C Robert, G V Long, J Larkin, J D Wolchok, J C Hassel, J-J Grob

Eur J Cancer· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neoadjuvant anti-PD-1 alone or in combination with anti-TIGIT or an oncolytic virus in resectable stage IIIB-D melanoma: a phase 1/2 trial.
Reinhard Dummer, Caroline Robert, Richard A Scolyer, Janis M Taube, Michael T Tetzlaff, Jean-Jacques Grob

Nat Med· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biomarker and pharmacodynamic activity of the transforming growth factor-beta (TGFβ) inhibitor SAR439459 as monotherapy and in combination with cemiplimab in a phase I clinical study in patients with advanced solid tumors.
Debbie Robbrecht, Jean-Jacques Grob, Oliver Bechter, Matteo Simonelli, Bernard Doger

Clin Transl Sci· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial.
John M Kirkwood, Michele Del Vecchio, Jeffrey Weber, Christoph Hoeller, Jean-Jacques Grob

Nat Med· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-Effectiveness Analysis of Sequential Treatment Strategies for Advanced Melanoma in Real Life in France.
Marguerite Kandel, Aurélie Bardet, Stéphane Dalle, Clara Allayous, Laurent Mortier, Jean-Jacques Grob

Curr Oncol· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improved pyrexia-related outcomes associated with an adapted pyrexia adverse event management algorithm in patients treated with adjuvant dabrafenib plus trametinib: Primary results of COMBI-APlus.
Victoria Atkinson, Caroline Robert, Jean J Grob, Helen Gogas, Caroline Dutriaux

Eur J Cancer· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma.
Hussein A Tawbi, Dirk Schadendorf, Evan J Lipson, Paolo A Ascierto, Luis Matamala, Jean-Jacques Grob

N Engl J Med· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term outcomes in patients with advanced melanoma who had initial stable disease with pembrolizumab in KEYNOTE-001 and KEYNOTE-006.
Omid Hamid, Caroline Robert, Adil Daud, Matteo S Carlino, Tara C Mitchell, Jean Jacques Grob

Eur J Cancer· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adjuvant therapy with pegylated interferon-alfa2b vs observation in stage II B/C patients with ulcerated primary: Results of the European Organisation for Research and Treatment of Cancer 18081 randomised trial.
Alexander M M Eggermont, Piotr Rutkowski, Caroline Dutriaux, Rainer Hofman-Wellenhof, Peter Dziewulski, Jean-Jacques Grob

Eur J Cancer· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pimasertib Versus Dacarbazine in Patients With Unresectable -Mutated Cutaneous Melanoma: Phase II, Randomized, Controlled Trial with Crossover.
Celeste Lebbé, Caroline Dutriaux, Thierry Lesimple, Willem Kruit, Joseph Kerger, Jean-Jacques Grob

Cancers (Basel)· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2019.
Claus Garbe, Teresa Amaral, Ketty Peris, Axel Hauschild, Petr Arenberger, Jean-Jacques Grob

Eur J Cancer· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.
James Larkin, Vanna Chiarion-Sileni, Rene Gonzalez, Jean-Jacques Grob, Piotr Rutkowski

N Engl J Med· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma.
Caroline Robert, Jean J Grob, Daniil Stroyakovskiy, Boguslawa Karaszewska, Axel Hauschild

N Engl J Med· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma.
Alexander M M Eggermont, Christian U Blank, Mario Mandala, Georgina V Long, Victoria Atkinson, Jean-Jacques Grob

N Engl J Med· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma.
Jeffrey Weber, Mario Mandala, Michele Del Vecchio, Helen J Gogas, Ana M Arance, Jean-Jacques Grob

N Engl J Med· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Features, Management, and Outcomes of Immune Checkpoint Inhibitor-Related Cardiotoxicity.
Marion Escudier, Jennifer Cautela, Nausicaa Malissen, Yann Ancedy, Morgane Orabona, Jean-Jacques Grob

Circulation· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.
Jedd D Wolchok, Vanna Chiarion-Sileni, Rene Gonzalez, Piotr Rutkowski, Jean-Jacques Grob

N Engl J Med· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy.
Alexander M M Eggermont, Vanna Chiarion-Sileni, Jean-Jacques Grob, Reinhard Dummer, Jedd D Wolchok

N Engl J Med· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.
James Larkin, Vanna Chiarion-Sileni, Rene Gonzalez, Jean Jacques Grob, C Lance Cowey

N Engl J Med· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis